IB Net Payout Yields Model

Invest like me - only at Covestor.com

cbdMD: The Wanted Pullback

By -

 

  • cbdMD reported a strong March quarter with net revenues growing 26%.
  • The pure-play CBD player guided December quarter sales to grow by 35% to reach nearly $16 million.
  • The stock is cheap at below 3x FY22 sales estimates that appear very low with the potential for the ingestible market to finally move forward.
  • Looking for a portfolio of ideas like this one? Members of Out Fox The Street get exclusive access to our model portfolio. Learn More »
The U.S. cannabidiol (CBD) space was a tough place to invest in the last year or so. cbdMD (YCBD) was a $6 stock back in mid-2019 and investors can now buy the stock sub-$3 despite the general bullish long-term view of the CBD space. My investment thesis is more bullish on the stock as the mass retailers look to move forward with stocking CBD-infused food products with or without FDA approval.

Read the full article on Seeking Alpha. 


Disclosure: No position mentioned. Please review the disclaimer page for more details. 


Update - August 15

cbdMD continues to struggle like most CBD related businesses. The company missed FQ3'21 revenue targets and cut FQ1'22 targets, but the stock did show initial signs of bottoming. 

  • -Q3 GAAP EPS of $0.02 beats by $0.04.
  • -Revenue of $10.6M (-0.4% Y/Y) misses by $1.95M.

Finviz Chart 
The company is still predicting strong growth, but product launch issues and FDA regulation delays just aren't helping. 

  • Due to production delays from vendors on new product launches, we are now are revising our net sales guidance for the first quarter of fiscal 2022 ending December 31, 2021 from range of $15.5 million to $16.25 million to range of $14.9 million to $15.5 million, or 20-25% YOY sales growth for the December, 2021 quarter.

Comments

Post a Comment

Popular posts from this blog

Aurora Cannabis: Deal Or No Deal

By -
Aurora Cannabis was left out of the major deal making in 2018. The cannabis company updated FQ2 guidance to revenues of $50 to $55 million with a continued focus on pure production growth. The stock is down as the market is becoming less impressed with commodity farming operations due to the prime Oregon example. The stock is below key resistance at $5.40 as medical cannabis patient totals failed to impress. As the end of 2018 came and went,   Aurora Cannabis   ( ACB ) was a notable absentee from the deal making in the cannabis market. Just about all of the other major Canadian cannabis players got large investments or signed up powerful partnerships, but the related stocks didn't generally maintain rallies following the deals. Based on the early legalization data in Canada and Oregon, the best option for Aurora Cannabis might actually be selling production capacity while the Canadian market remains hot. Read the full article on Seeking Alpha.  Disclosure: No
Read more

C3.ai: Out Of Steam (Rating Downgrade)

By -
Image
This idea was discussed in more depth with members of my private investing community, Out Fox The Street.  Learn More »   Update - June 23, 2023 C3.ai has fallen back to earth after the Investor Day meeting. The Deutsche Bank analyst call on the meeting suggests the company still isn't ready to produce actual numbers from the generative AI demand.  C3.ai ( NYSE: AI ) shares  fell more than 8%  on Friday after investment firm Deutsche Bank reiterated its sell rating on the enterprise software company after it held its investor meeting. Analyst Brad Zelnick said the event "left a lot to be desired" as there were  no details on financials, "limited" updates on the company's operations and investors did not really attend the event, despite it being positioned as for them. "While we appreciate the vast opportunity presented by AI, the event did nothing to ease our skepticism on the true differentiation of the company's platform, its traction with custome
Read more

Archer Aviation: Promising Developments

By -
Image
  Update - June 12, 2023 Archer is finally in the midst of a breakout on the positive FAA news.  -The acting administrator of the Federal Aviation Administration, Billy Nolen, is in talks to join Archer Aviation (NYSE:ACHR), per a report from Reuters. -Citing sources familiar with the situation, the report indicates Nolen will depart his current position atop the FAA in the next few weeks and will then look to transition to a role at Archer (ACHR). Archer’s rival Joby Aviation (JOBY) previously appointed former FAA chief Michael Huerta to a position on its board in March. Original article posted on Jan. 19 This idea was discussed in more depth with members of my private investing community, Out Fox The Street.  Learn More »   Archer Aviation Inc. jumped to $3 on the excitement of small insider purchases. The eVTOL manufacturer recently announced several major developments towards FAA certification and production of the Midnight aircraft. Archer Aviation stock is interesting, with a $70
Read more